US2021128647A1PendingUtilityA1

Spore-based probiotic supplementation in dogs and control of endotoxemia

56
Assignee: MICROBIOME LABS LLCPriority: Sep 16, 2019Filed: Sep 16, 2020Published: May 6, 2021
Est. expirySep 16, 2039(~13.1 yrs left)· nominal 20-yr term from priority
Inventors:Kiran KrishnanDale M. KrizThomas F. Bayne
A23K 50/42A23K 10/18A23L 33/135A23K 50/40A61K 35/744A61K 35/742A61K 9/0053A61P 1/14A61P 31/04A61P 1/00
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention is directed to methods of administering a probiotic composition including Bacillus subtilis, Bacillus licheniformis, and Pediococcus acidilactici to dogs to decrease endotoxemia and improve the digestive process, and related methods.

Claims

exact text as granted — not AI-modified
1 . A method of decreasing endotoxemia in a dog comprising the steps of:
 a. providing a probiotic composition comprising  Bacillus subtilis, Bacillus licheniformis , and  Pediococcus acidilactici , and   b. administering the probiotic composition to the dog in an amount effective to decrease endotoxemia in the dog.   
     
     
         2 . The method of  claim 1 , wherein said  Bacillus subtilis  is  Bacillus subtilis  HU58 and/or said  Bacillus licheniformis  is  Bacillus licheniformis  SL-307. 
     
     
         3 . The method of  claim 1 , wherein said  Bacillus subtilis, Bacillus licheniformis , and  Pediococcus acidilactici  total about 1 billion to about 10 billion CFU. 
     
     
         4 . The method of  claim 3 , wherein said CFU total is about 2.5 billion to about 5 billion CFU. 
     
     
         5 . The method of  claim 3 , wherein said CFU total is about 2 billion CFUs  Bacillus subtilis  HU58, about 500 million to 1 billion CFUs  Pediococcus acidilactici , and about 100 million CFUs of  Bacillus licheniformis.    
     
     
         6 . The method of  claim 1 , wherein said probiotic composition is orally administered to the dog. 
     
     
         7 . The method of  claim 4 , wherein said oral administration is for at least 30 days. 
     
     
         8 . The method of  claim 1 , wherein said dog is a healthy dog. 
     
     
         9 . The method of  claim 1 , wherein said dog has a disorder of the gastrointestinal tract. 
     
     
         10 . A method of improving digestion in the gastrointestinal tract of a dog comprising the steps of:
 a. providing a probiotic composition comprising  Bacillus subtilis, Bacillus licheniformis , and  Pediococcus acidilactici , and   b. administering the probiotic composition to the dog in an amount effective to improve the digestive process in gastrointestinal tract of the dog.   
     
     
         11 . The method of  claim 10 , wherein said  Bacillus subtilis  is  Bacillus subtilis  HU58 and/or said  Bacillus licheniformis  is  Bacillus licheniformis  SL-307. 
     
     
         12 . The method of  claim 10 , wherein said  Bacillus subtilis, Bacillus licheniformis , and  Pediococcus acidilactici  total about 1 billion to about 10 billion CFU. 
     
     
         13 . The method of  claim 12 , wherein said CFU total is about 2.5 billion to about 5 billion CFU. 
     
     
         14 . The method of  claim 12 , wherein said CFU total is about 2 billion CFUs  Bacillus subtilis  HU58, about 500 million to 1 billion CFUs  Pediococcus acidilactici , and about 100 million CFUs of  Bacillus licheniformis.    
     
     
         15 . The method of  claim 12 , wherein said probiotic composition is orally administered to the dog. 
     
     
         16 . The method of  claim 15 , wherein said oral administration is for at least 30 days. 
     
     
         17 . The method of  claim 1 , wherein said dog is a healthy dog. 
     
     
         18 . The method of  claim 1 , wherein said dog has a disorder of the gastrointestinal tract. 
     
     
         19 . A method of treating a digestive disorder in a dog comprising the steps of:
 a. providing a probiotic composition comprising  Bacillus subtilis, Bacillus licheniformis , and  Pediococcus acidilactici , and   b. administering the probiotic composition to the dog in an amount effective to decrease or eliminate a digestive disorder symptom in the dog.   
     
     
         20 . The method of  claim 19 , wherein said  Bacillus subtilis  is  Bacillus subtilis  HU58 and/or said  Bacillus licheniformis  is  Bacillus licheniformis  SL-307. 
     
     
         21 . The method of  claim 19 , wherein said  Bacillus subtilis, Bacillus licheniformis , and  Pediococcus acidilactici  total about 1 billion to about 10 billion CFU. 
     
     
         22 . The method of  claim 21 , wherein said CFU total is about 2.5 billion to about 5 billion CFU. 
     
     
         23 . The method of  claim 21 , wherein said CFU total is about 2 billion CFUs  Bacillus subtilis  HU58, about 500 million to 1 billion CFUs  Pediococcus acidilactici , and about 100 million CFUs of  Bacillus licheniformis.    
     
     
         24 . The method of  claim 19 , wherein said probiotic composition is orally administered to the dog. 
     
     
         25 . The method of  claim 22 , wherein said oral administration is for at least 30 days.

Join the waitlist — get patent alerts

Track US2021128647A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.